February 18, 2026

Zacks Small-Cap Research

Sponsored – Impartial - Comprehensive

Michael Kim
312-265-9371
email@zacks.com

scr.zacks.com
101 N. Wacker Drive, Chicago, IL 60606

Earth Science Tech, Inc. (ETST-OTC)

ETST: F3Q26 Earnings – Increasing Visibility into Accelerating Growth and Stronger Financial Performance

ETST reported F3Q26 (Dec) EPS of $0.003, or just shy of our $0.005 estimate, with the miss mostly a function of modestly lower revenues partially offset by improving operating efficiencies. Edging down our F2026 (Mar) and F2027 EPS estimates by a penny to $0.01 and $0.03, respectively, reflecting a slightly flatter revenue growth trajectory. No change to our DCF-derived price target of $1.00 suggesting meaningful upside potential from current levels.

Current Price (2/17/26)	$0.13
Valuation	**$1.00**

OUTLOOK

Key F3Q26 takeaways include: 1) we look for a number of powerful catalysts to increasingly drive accelerating revenue growth including ongoing initiatives to broaden product and distribution capabilities, thereby expanding ETST's TAM; 2) management announced a series of initiatives designed to institutionalize the business, attract new investors, and drive long-term value creation including pending votes on the potential retirement of ETST's Series B Preferred Stock, as well as "say on pay" to better align management incentives with shareholder interests.; and 3) key margin expansion drivers likely include an ongoing sales mix shift in favor of non-sterile compounding medications (carrying higher gross margins), compensation relief (assuming shareholder approval), and ETST's holding company structure that enables subsidiaries to leverage centralized corporate functions.

SUMMARY DATA

52-Week High	**$0.24**
52-Week Low	**$0.00**
One-Year Return (%)	**-36.59**
Beta	**N/A**
Average Daily Volume (sh)	**54,328**
Shares Outstanding (mil)	**292.8**
Market Capitalization ($mil)	**$38**
Short Interest Ratio (days)	**N/A**
Institutional Ownership (%)	**0**
Insider Ownership (%)	**47**
Annual Cash Dividend	**$0.00**
Dividend Yield (%)	**0.00**
5-Yr. Historical Growth Rates	
Sales (%)	**N/A**
Earnings Per Share (%)	**N/A**
Dividend (%)	**N/A**
P/E using TTM EPS	**N/A**
P/E using F2026 Estimate	**13.0**
P/E using F2027 Estimate	**4.3**

Risk Level	**Above-Average**
Type of Stock	**Small-Growth**
Industry	**Medical - Products**

ZACKS ESTIMATES

Revenues
(in thousands of $)

	Q1 (Jun)	Q2 (Sep)	Q3 (Dec)	Q4 (Mar)	Year (Mar)
2024	220 A	1,928 A	3,790 A	6,016 A	11,954 A
2025	8,569 A	8,519 A	7,353 A	8,677 A	33,118 A
2026	8,760 A	9,051 A	8,387 A	8,906 E	35,103 E
2027					43,216 E

Earnings/Share

	Q1 (Jun)	Q2 (Sep)	Q3 (Dec)	Q4 (Mar)	Year (Mar)
2024	($0.00) A	$0.00 A	$0.00 A	$0.00 A	$0.00 A
2025	$0.00 A	$0.00 A	$0.00 A	$0.00 A	$0.01 A
2026	$0.00 A	$0.00 A	$0.00 A	$0.01 E	$0.01 E
2027					$0.03 E

Quarterly revenues/EPS may not equal annual revenues/EPS due to rounding.

F3Q26 EARNINGS: EPS A BIT SHY, BUT OPERATING LEVERAGE INCREASINGLY SHINING THROUGH

On 2/17/26, Earth Science Tech reported F3Q26 earnings and filed the company's 10-Q for the three months ended December 31, 2025. For the quarter, ETST reported net income of $0.9 million, or $0.003 per share, just shy of our $0.005 estimate. Relative to our model, a revenue shortfall and less favorable non-operating trends were partially offset by lower operating expenses (Exhibit 1).

Focusing on the top line, ETST generated $8.4 million of revenue in F3Q26, below our $10.0 million forecast, but up from $7.4 million for the year-ago quarter. Relative to our model, the variance was seemingly mostly a function of adverse seasonality as well as a temporary Active Pharmaceutical Ingredients (API) supply issues in India and China in November and December (which have subsequently been fully resolved). After factoring in cost of goods sold of $2.0 million, gross profit totaled $6.4 million for F3Q26 representing a gross margin of 76.3% compared to 69.2% for the prior-year quarter.

In aggregate, ETST's operating expenses totaled $5.1 million for F3Q26, down from $6.1 million for F2Q26, and came in 17% below our $6.1 million forecast. Much of the favorable variance related to lower compensation, partially offset by higher general and administrative costs.

Turning to the balance sheet, assets totaled $8.1 million, including cash of $416,000 as of December 31, 2025. By comparison, assets totaled $5.7 million as of December 31, 2024, inclusive of $522,000 of cash on the balance sheet. Adjusted EBITDA totaled $1.2 million for F3Q26, up from just $300,000 for the year-ago quarter. Turning to share buybacks, management repurchased 1,143,000 and 3,703,296 shares of common stock during F3Q26 and the first three quarters of F2026, respectively, thereby reducing the number of outstanding shares by 3.6% over the last 12 months.

Exhibit 1: F3Q26 GAAP Actual vs. Estimates
($ thousands)

	F3Q26		Change	
	Actual	Estimate	$	%
Revenue	**8,387**	**9,956**	**(1,569)**	**-15.8%**
Cost of goods sold	1,988	2,709	(721)	-26.6%
Gross Profit	6,399	7,247	(848)	-11.7%
Operating Expenses:				
Salaries expenses	2,931	4,032	(1,101)	-27.3%
General and administrative expense	914	796	118	14.8%
Marketing	709	764	(56)	-7.3%
Bank charges	250	232	19	8.1%
Insurance expense	40	46	(6)	-13.3%
Legal and professional fees	56	50	6	12.5%
Depreciation and amortization	122	148	(26)	-17.5%
Utilities	35	45	(10)	-22.0%
Total Operating Expenses	**5,057**	**6,113**	**(1,056)**	**-17.3%**
Operating Income/(Loss)	**1,342**	**1,134**	**208**	**18.3%**
Other Income/(Expense):				
Net realized gain on sale of investments	310	200	110	54.9%
Dividend income	5	9	(4)	-48.2%
Unrealized loss of FV changes of investments	(614)	150	(764)	-509.2%
Other income	0	0	0	NM
Interest expense	(5)	(7)	2	-29.1%
Other income/(expenses), net	(304)	352	(656)	-186.3%
Pre-Tax Income/(Loss)	**1,038**	**1,486**	**(448)**	**-30.1%**
Income taxes	(128)	0	(128)	NM
Net Income/(Loss)	**910**	**1,486**	**(576)**	**-38.7%**
Earnings/(loss) per share	**$0.003**	**$0.005**	**($0.00)**	**-38.9%**
Weighted avg shares out (basic & diluted)	292,804	292,163	642	0.2%

Source: Company Reports and Zacks Small Cap Research estimates and calculations.

KEY TAKEAWAYS

Following our review of F3Q26 results, we highlight the following key takeaways:

1. **Accelerating revenue growth:** Going forward, we look for a number of powerful catalysts to increasingly drive accelerating revenue growth across a number of ETST's subsidiaries. At a high level, ongoing initiatives to broaden product and distribution capabilities across businesses likely drive more sustainable revenue growth, with management recently stepping up inventory investments ahead of accelerating sales volumes. More specifically, Peaks, ETST's telemedicine platform, generated $843 million of sales in F3Q26 (translating into a $3.4 million annualized run-rate), up 45% on a sequential-quarter basis and nearly 670% versus the prior-year quarter. Looking ahead, we forecast continued growth in sales, particularly as fulfillment capabilities expand. Importantly, related revenues carry high incremental margins, with the underlying mix skewing more in favor of recurring prescriptions (currently around 40% to 45%) as opposed to one-time sales. Next, RXCompound and Mister Meds continue to build out complementary distribution footprints, with 12 additional state licenses pending. Assuming related applications are approved (potentially in the next few months), broader geographic reach meaningfully expands ETST's Total Addressable Market (TAM) and revenue profile. Finally, MyOnlineConsultation.com (MOC) – a referral platform to facilitate consultations for compounded prescription medications – is scheduled to launch in the next few months, with support from Villas Health's doctor network and RxCompound's fulfillment capabilities.

2. **Prioritizing corporate governance and capital efficiency:** In conjunction with F3Q26 results, management announced a series of initiatives designed to institutionalize the business, attract new investors, and drive long-term value creation. From a corporate governance perspective, senior executives and the Board of Directors remain focused on enhancing shareholder engagement and transparency. Indeed, shareholders are set to vote on the potential retirement of ETST's Series B Preferred Stock, which would seemingly allow certain institutional investors to take positions in the stock (though a shift in capital structure combined with compensation adjustments may trigger senior management turnover). Furthermore, the Board continues to contemplate uplisting the stock to the OTCQB, OTCQX, or a senior exchange to enhance liquidity (though any potential transition would likely come with a step up in compliance costs/requirements). Next, the management team continues to explore the divestiture of non-core assets (likely Magnefuse despite the company's recent positive inflection in cash flows), as well as consolidating subsidiaries to further optimize the portfolio and enhance operating efficiencies. Finally, in addition to recently-voided employment contracts and lower Board compensation rates (generating ~$1.4 million in annualized cost savings for F4Q26 and potentially beyond), shareholders are set for a "say on pay" advisory vote to approve or disapprove of the compensation for top executives, with the goal of better aligning management incentives with shareholder interests.

3. **Rising margins/earnings power:** ETST's operating margin expanded from 3.1% in F3Q25 to 16.0% in F3Q26, with further expansion to come, we believe. Beyond strong revenue growth, key drivers are likely to include elevated gross margins at RXCompound and Peaks Curative, compensation relief (assuming shareholder approval), and ETST's holding company structure enables subsidiaries to leverage centralized corporate functions including information technology, marketing, finance/accounting, and legal, amongst others, thereby streamlining expenses across the portfolio. In addition, assuming an ongoing sales mix shift in favor of non-sterile compounding medications (carrying higher gross margins) and away from weight-loss products given rising competition, regulatory uncertainty, and supply challenges suggests further upside in gross margins. From a cash flow perspective, ETST generated $1.2 million of positive cash from operations through the first three quarters of F2026, with four subsidiaries currently generating positive cash flows compared to just one in F2024.

FINETUNING EPS ESTIMATES

Our updated model calls for EPS to total $0.01 for fiscal year 2026 (ending March 31, 2026) followed by $0.03 in F2027, with further growth expected in F2028 and beyond as the business continues to scale and operating efficiency initiatives increasingly take hold. Our model updates included a slightly flatter revenue growth trajectory offset by more favorable margin assumptions.

Focusing on the top line, we project revenue growth to remain strong – $35.1 million in F2026 followed by $43.2 million in F2027, representing a year-over-year growth rate of 23%. Key growth drivers likely include rising sales at Peaks Curative, with an expanding fulfillment footprint assuming RXCompound wins incremental state licenses, building momentum at Mister Meds following the company's commencement of operations, and the recent additions of Las Villas and DOConsultations.com.

MAINTAINING PRICE TARGET

Turning to valuation, we are leaving our DCF-derived price target unchanged at $1.00. We see meaningful upside potential from current levels, as ETST continues to trade at what we believe to be an unsustainably low valuation despite the company's unique business model, compelling growth track record, improving profitability, and strong balance sheet. In our minds, much of the ETST's steep discount can be attributed to a lack of awareness across the investment community, particularly considering the stock's OTC listing, more limited liquidity, and undersized market cap. That said, we look for a considerable upward revaluation for the stock, as awareness and appreciation of the company's business model, growth prospects, competitive positioning, profitability, and valuation disconnect increasingly take hold.

Moreover, while apples-to-apples comparisons for ETST remain challenging given the company's unique business model as well as the lack of truly comparable publicly-traded stocks, our curated peer group of publicly-traded compound pharmacy companies, traditional pharmacy retailers, and telehealth providers continues to trade at meaningfully higher Price-to-Earnings and EBITDA multiples suggesting meaningful upside for the stock should the shares trade closer to peer-like multiples.

INVESTMENT THESIS

Earth Science Tech is a strategic holding company, with wholly-owned subsidiaries operating in the compounding pharmaceutical, telehealth, real estate, and consumer products sectors. Senior executives remain focused on managing and optimizing company operations, as well as acquiring complementary assets.

Our investment thesis revolves around:

1. **Industry tailwinds:** In contrast to standardized prescription drugs manufactured in mass by largescale pharmaceutical companies, compounding pharmacies formulate customized medications tailored for specific individual needs. In aggregate, revenues across the U.S. compounding pharmacy market are projected to rise from $6.3 billion in 2024 to $10.8 billion in 2033 representing a 6.1% Compound Annual Growth Rate (CAGR). Much of the growth across the industry can be attributed to: a) rising demand for personalized medications; b) emerging compounding technologies including Artificial Intelligence (AI) to enhance safety, efficacy, productivity, and efficiencies; c) Therapeutic Area (TA) expansion, with a focus on weight loss, Hormone Replacement Therapy (HRT), and chronic disease treatments; and d) ongoing supply shortages opening the door for compounding pharmacies to fill the gaps left by drug manufacturers.

   Telehealth/telemedicine businesses provide digital healthcare services via video, phone, or online platforms. Looking ahead, revenues across the U.S. market are forecast to rise from $35.8 billion in 2024 to $160.5 billion in 2034 translating into a 16.2% CAGR. Key growth drivers likely include: a) rising adoption of telehealth services reflecting ubiquitous internet availability and smartphones, enhanced convenience/accessibility, and lower costs; b) deepening integration of technologies (particularly AI) to augment telehealth capabilities; c) the COVID-19 pandemic and related lockdowns hastened the uptake of virtual consultations and remote patient monitoring; and d) healthcare providers increasingly leveraging digital channels to manage chronic conditions.

2. **Real estate optionality:** Avenvi, acquired in late 2024, is a real estate investment/financing company with a diversified portfolio of assets. Beyond sourcing locations for ETST's other portfolio companies, Avenvi remains well positioned to generate accelerating revenue/earnings contributions, particularly as the company's community of single-family homes comes to market. Stepping back, the Florida housing market continues to stabilize, with favorable lead indicators around: a) positive macroeconomic, demographic, and mortgage rate trends likely drive accelerating sales going forward; b) home prices remain relatively steady; c) new listings continue to trend higher, thereby building inventory; and d) supply/inventory and demand/sales rates are generally in balance suggesting a constructive backdrop for both buyers and sellers.

3. **Multiple growth drivers:** We look for ETST revenues to continue to step higher reflecting several powerful drivers. First, following a period of active M&A, we forecast meaningful growth related to activating newly acquired assets. More specifically, we anticipate Peaks Curative sales to continue to ramp up, particularly as RXCompound obtains licenses in new states. Furthermore, we note Mister Meds recently commenced compounding sterile medications, and fiscal year 2026 (ending March 31, 2026) revenues will incorporate a full year of contributions from Avenvi, Las Villas, DOConsultations.com, and MagneCHEF. Second, we foresee ongoing consolidation across the compounding pharmacy industry, with market shares continuing to roll up to scale-enabled, diversified players. To the point, smaller independent providers with concentrated product/payer profiles likely increasingly struggle to pivot considering the shifting regulatory landscape. Third, management recently expanded the sales team and launched marketing initiatives to broaden awareness across physicians/healthcare providers, with the goal of driving stepped-up growth in fulfillments and refills.

INVESTMENT RISKS

1. **Regulatory uncertainty:** At a high level, ETST must adhere to complicated healthcare laws and regulations at both the state and federal levels, and remains subject to substantial penalties in the event of any violations. Moreover, management continues to allocate considerable financial resources and mindshare to maintain compliance with shifting rules and regulations. More specifically, drugmakers are increasingly focused on compounding pharmacies and telehealth companies that have customized concentrations, ingredients, and/or delivery systems to commercialize bespoke and more affordable versions of brand-name blockbuster drugs wherein demand trends far outstripped supply. Selected supply shortages have ended (according to the FDA), seemingly paving the way for stepped-up patent infringement litigation risk, as pharmaceutical manufacturers increasingly look to recapture previously foregone economics.

2. **Elevated competition:** To be sure, the healthcare industry remains quite fragmented and highly competitive. Furthermore, larger/well-established companies, with considerable infrastructure, resource, branding, and financial advantages often garner outsized market shares, particularly given burdensome regulatory backdrops. More specifically, specialty compounding pharmacies compete with larger healthcare providers and more traditional pharmacy retailers, with broader footprints and more favorable brand awareness/loyalty.

3. **Junior exchange listing:** ETST recently uplisted to the new OTCID market. That said, shares listed on the OTC markets are generally subject to less onerous regulation/transparency, higher volatility, lower liquidity/trading volumes, and wider bid/ask spreads relative to senior exchanges (NYSE, Nasdaq). Moreover, should management opt to raise capital via an underwritten transaction to finance organic growth and/or M&A, an equity offering likely translates into downward pressure on the stock, as well as meaningful dilution to existing shareholders.

4. **Incremental M&A execution/integration:** While management seems reluctant to pull the trigger on further M&A transactions in the near term (other than purchases of hard assets), a key component of ETST's strategic holding company business model remains the acquisition of complementary operating companies to enhance growth. All transactions carry meaningful execution and operational risks. Furthermore, shareholders likely risk dilution, assuming prospective deals are at least partially financed with equity. Finally, business dislocations often follow changes-of-control, which can materially compromise near-term financial performance and/or longer-term returns on investments.

PROJECTED INCOME STATEMENT

Earth Science Tech, Inc.
($ thousands)

	Quarterly								Annual				Y/Y Growth		
	F1Q25	F2Q25	F3Q25	F4Q25	F1Q26	F2Q26	F3Q26	F4Q26E	F2024	F2025	F2026E	F2027E	F2025	F2026E	F2027E
	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25	Mar-26	Mar-24	Mar-25	Mar-26	Mar-27	Mar-25	Mar-26	Mar-27
Revenue	**8,569**	**8,519**	**7,353**	**8,677**	**8,760**	**9,051**	**8,387**	**8,906**	**11,954**	**33,118**	**35,103**	**43,216**	**177%**	**6%**	**23%**
Cost of goods sold	2,158	2,252	2,266	2,141	2,669	2,327	1,988	2,111	4,125	8,817	9,095	10,243	114%	3%	13%
Gross Profit	**6,410**	**6,267**	**5,087**	**6,536**	**6,091**	**6,724**	**6,399**	**6,795**	**7,828**	**24,300**	**26,009**	**32,973**	**210%**	**7%**	**27%**
Operating Expenses:															
Salaries expenses	3,335	3,606	3,298	3,877	3,801	4,050	2,931	3,113	4,359	14,116	13,895	15,104	224%	-2%	9%
General and administrative expense	61	1,259	810	2,025	980	888	914	953	174	4,155	3,735	4,278	2294%	-10%	15%
Marketing	211	153	346	127	634	740	709	752	25	837	2,835	3,651	3210%	239%	29%
Bank charges	289	271	211	296	255	220	250	266	423	1,067	991	1,290	152%	-7%	30%
Rent expense	42	0	0	(42)	0	0	0	0	11	0	0	0	-100%	NM	NM
Insurance expense	36	45	80	20	44	42	40	43	5	180	170	208	3262%	-6%	22%
Legal and professional fees	1,337	63	62	(1,155)	73	12	56	59	1,774	306	200	289	-83%	-34%	44%
Depreciation and amortization	30	33	45	43	35	148	122	122	150	152	426	487	1%	181%	14%
Utilities	5	6	10	19	27	41	35	37	15	40	140	179	163%	246%	28%
Total Operating Expenses	**5,345**	**5,437**	**4,861**	**5,209**	**5,849**	**6,141**	**5,057**	**5,345**	**6,936**	**20,852**	**22,392**	**25,486**	**201%**	**7%**	**14%**
Operating Income/(Loss)	**1,065**	**830**	**226**	**1,327**	**242**	**583**	**1,342**	**1,450**	**892**	**3,448**	**3,617**	**7,488**	**286%**	**5%**	**107%**
Other Income/(Expense):															
Net realized gain on sale of investments	0	0	175	126	82	146	310	200	0	300	737	800	NM	146%	9%
Dividend income	0	0	9	0	2	9	5	5	0	9	20	18	NM	122%	-11%
Unrealized loss of FV changes of investments	0	0	(197)	(168)	135	216	(614)	150	0	(366)	(112)	600	NM	NM	NM
Other income	13	0	0	(13)	0	0	0	0	0	0	1	2	NM	NM	100%
Interest expense	(2)	(3)	(6)	(10)	(4)	(7)	(5)	(4)	(67)	(21)	(21)	(17)	NM	NM	NM
Other income/(expenses), net	11	(3)	(20)	(66)	215	363	(304)	351	(67)	(78)	625	1,403	NM	NM	124%
Pre-Tax Income/(Loss)	**1,076**	**827**	**206**	**1,261**	**457**	**946**	**1,038**	**1,801**	**825**	**3,370**	**4,242**	**8,890**	**308%**	**26%**	**110%**
Income taxes	0	(28)	0	(88)	0	0	(128)	(222)	(13)	(117)	(350)	(1,096)	NM	NM	NM
Net Income/(Loss)	**1,076**	**798**	**206**	**1,173**	**457**	**946**	**910**	**1,579**	**812**	**3,254**	**3,892**	**7,795**	**301%**	**20%**	**100%**
Earnings/(loss) per share	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.00**	**$0.01**	**$0.00**	**$0.01**	**$0.01**	**$0.03**	**309%**	**24%**	**103%**
Weighted avg shares out (basic & diluted)	309,941	306,047	302,886	295,212	294,509	293,543	292,804	291,145	309,687	303,521	293,000	288,645	-2%	-3%	-1%

Source: Company reports and Zacks SCR estimates and calculations.

PROJECTED BALANCE SHEET

Earth Science Tech, Inc.
($ thousands)

	Quarterly								Annual				Y/Y Growth		
	F1Q25	F2Q25	F3Q25	F4Q25	F1Q26	F2Q26	F3Q26	F4Q26E	F2024	F2025	F2026E	F2027E	F2025	F2026E	F2027E
	Jun-24	Sep-24	Dec-24	Mar-25	Jun-25	Sep-25	Dec-25	Mar-26	Mar-24	Mar-25	Mar-26	Mar-27	Mar-25	Mar-26	Mar-27
Assets															
Current assets:															
Cash	1,384	1,532	522	1,473	878	1,235	416	916	698	1,473	916	2,916	111%	-38%	218%
Accounts Receivable	318	204	164	129	342	227	306	309	235	129	309	322	-45%	140%	4%
Equity Investments at fair value	0	0	1,101	645	887	990	1,126	1,149	0	645	1,149	1,241	NM	78%	8%
Inventory	239	432	138	504	812	1,045	1,088	1,099	316	504	1,099	1,143	60%	118%	4%
Deposits	14	23	33	338	52	32	58	58	9	338	58	61	3515%	-83%	4%
Prepaid	124	90	48	21	111	73	39	40	0	21	40	41	NM	91%	4%
Total current assets	2,080	2,281	2,005	3,111	3,081	3,603	3,033	3,570	1,258	3,111	3,570	5,723	147%	15%	60%
Property and Equipment, net	217	216	1,123	1,384	1,638	1,855	1,891	1,910	135	1,384	1,910	1,986	923%	38%	4%
Right of use asset, net	139	220	190	172	226	183	139	141	157	172	141	146	10%	-18%	4%
Goodwill	2,303	2,303	2,303	2,303	2,649	2,649	2,649	2,649	2,303	2,303	2,649	2,649	0%	15%	0%
Intangible Assets, net	34	30	87	97	185	378	378	378	28	97	378	378	241%	290%	0%
Total Assets	**4,772**	**5,050**	**5,708**	**7,067**	**7,779**	**8,667**	**8,089**	**8,647**	**3,881**	**7,067**	**8,647**	**10,881**	**82%**	**22%**	**26%**
Liabilities															
Current liabilities:															
Accounts payable	221	392	46	492	960	1,047	1,089	1,099	531	492	1,099	1,143	-7%	123%	4%
Accrued expenses and other payable	1,161	1,158	1,395	2,322	2,247	2,315	1,019	1,029	855	2,322	1,029	1,070	172%	-56%	4%
Current portion of operating lease obligations	70	118	118	122	160	160	122	122	70	122	122	122	73%	0%	0%
Current portion of loans and obligations	31	31	755	210	31	31	31	31	31	210	31	31	587%	-85%	0%
Total current liabilities	1,483	1,699	2,315	3,146	3,397	3,552	2,260	2,281	1,487	3,146	2,281	2,366	112%	-27%	4%
Lease liability less current maturities	68	101	70	38	71	24	18	18	85	38	18	19	-55%	-52%	4%
Equipment loans and obligations non-current	54	49	43	31	25	16	8	8	61	31	8	8	-48%	-74%	0%
Total Liabilities	**1,605**	**1,848**	**2,428**	**3,216**	**3,492**	**3,592**	**2,286**	**2,308**	**1,632**	**3,216**	**2,308**	**2,394**	**97%**	**-28%**	**4%**
Total Shareholders' Equity	**3,167**	**3,201**	**3,280**	**3,851**	**4,287**	**5,076**	**5,803**	**6,339**	**2,249**	**3,851**	**6,339**	**8,488**	**71%**	**65%**	**34%**
Total Liabilities & Shareholders' Equity	**4,772**	**5,050**	**5,708**	**7,067**	**7,779**	**8,667**	**8,089**	**8,647**	**3,881**	**7,067**	**8,647**	**10,881**	**82%**	**22%**	**26%**

Source: Company reports and Zacks SCR estimates and calculations.

HISTORICAL STOCK PRICE



DISCLOSURES

The following disclosures relate to relationships between Zacks Small-Cap Research ("Zacks SCR"), a division of Zacks Investment Research ("ZIR"), and the issuers covered by the Zacks SCR Analysts in the Small-Cap Universe.

ANALYST DISCLOSURES

I, Michael Kim, hereby certify that the view expressed in this research report accurately reflect my personal views about the subject securities and issuers. I also certify that no part of my compensation was, is, or will be, directly or indirectly, related to the recommendations or views expressed in this research report. I believe the information used for the creation of this report has been obtained from sources I considered to be reliable, but I can neither guarantee nor represent the completeness or accuracy of the information herewith. Such information and the opinions expressed are subject to change without notice.

INVESTMENT BANKING AND FEES FOR SERVICES

Zacks SCR does not provide investment banking services nor has it received compensation for investment banking services from the issuers of the securities covered in this report or article.
Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm engaged by the issuer for providing non-investment banking services to this issuer and expects to receive additional compensation for such non-investment banking services provided to this issuer. The non-investment banking services provided to the issuer includes the preparation of this report, investor relations services, investment software, financial database analysis, organization of non-deal road shows, and attendance fees for conferences sponsored or co-sponsored by Zacks SCR. The fees for these services vary on a per-client basis and are subject to the number and types of services contracted. Fees typically range between ten thousand and fifty thousand dollars per annum. Details of fees paid by this issuer are available upon request.

POLICY DISCLOSURES

This report provides an objective valuation of the issuer today and expected valuations of the issuer at various future dates based on applying standard investment valuation methodologies to the revenue and EPS forecasts made by the SCR Analyst of the issuer's business.
SCR Analysts are restricted from holding or trading securities in the issuers that they cover. ZIR and Zacks SCR do not make a market in any security followed by SCR nor do they act as dealers in these securities. Each Zacks SCR Analyst has full discretion over the valuation of the issuer included in this report based on his or her own due diligence. SCR Analysts are paid based on the number of companies they cover. SCR Analyst compensation is not, was not, nor will be, directly or indirectly, related to the specific valuations or views expressed in any report or article.

ADDITIONAL INFORMATION

Additional information is available upon request. Zacks SCR reports and articles are based on data obtained from sources that it believes to be reliable, but are not guaranteed to be accurate nor do they purport to be complete. Because of individual financial or investment objectives and/or financial circumstances, this report or article should not be construed as advice designed to meet the particular investment needs of any investor. Investing involves risk. Any opinions expressed by Zacks SCR Analysts are subject to change without notice. Reports or articles or tweets are not to be construed as an offer or solicitation of an offer to buy or sell the securities herein mentioned.

CANADIAN COVERAGE

This research report is a product of Zacks SCR and prepared by a research analyst who is employed by or is a consultant to Zacks SCR. The research analyst preparing the research report is resident outside of Canada, and is not an associated person of any Canadian registered adviser and/or dealer. Therefore, the analyst is not subject to supervision by a Canadian registered adviser and/or dealer, and is not required to satisfy the regulatory licensing requirements of any Canadian provincial securities regulators, the Investment Industry Regulatory Organization of Canada and is not required to otherwise comply with Canadian rules or regulations.